Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ethanol extract of Tubtim Chumphae rice bran downregulates SRD5A gene expression, similarly to finasteride, suggesting potential use as an anti-hair loss product.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

This study found that women taking 5α-reductase inhibitors (5aRI) for alopecia had a lower risk of breast cancer compared to those not using these medications, with no increased risk of developing ovarian or endometrial cancer.

In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

This study reports that using 5-alpha reductase inhibitors is associated with a 31% increased risk of depression, highlighting that the choice of comparator group significantly affects study results.

This study suggests that using opioids along with 5αRI may reduce opioid use disorder risk in humans, supporting similar findings from animal studies.

This study analyzed reports from the FDA Adverse Event Reporting System and observed an upward trend in suicidality-related safety signals among young male finasteride users since 2019, peaking in 2022, highlighting emerging psychiatric safety concerns and the need for vigilant monitoring of this population.

This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.

This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

This source reports that combining 5-alpha reductase inhibitors with minoxidil for treating male androgenic alopecia presents a minimal risk of side effects when administered following established medical guidelines, with finasteride commonly associated with reversible sexual side effects and dutasteride used off-label with similar risks.

In this study, researchers found a statistically significant increase in reports of suicidality and depression associated with finasteride use, especially in younger individuals, whereas dutasteride showed no significant signal for suicidality and a weaker signal for depression.

Results are not reported in this commentary, but it discusses the influence of different control group choices—an active-comparator versus non-drug users—on measuring depression risk in studies of 5-alpha reductase inhibitors.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This study proposes that the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia may contribute to poorer COVID-19 prognosis in males.

This study found that use of 5-alpha reductase inhibitors for benign prostatic hyperplasia was not associated with an increased risk of hip fracture in men.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study found that finasteride treatment in male rats led to enduring effects on depressive-like behavior, hippocampal neurogenesis and neuroinflammation, and gut microbiota composition after withdrawal.

This study explored the effects of USPlus® DERM, a bioactive fatty acid extract from Serenoa repens, in promoting hair growth and enhancing hair follicle stem cell stemness in an ex vivo setting, showing potential for both 5‐α reductase-dependent and independent hair loss treatments.

This review discusses the potential benefits and risks of 5α-reductase inhibitors in preventing prostate cancer and reports no new results.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

This study found that certain curcumin analogs derived from natural plant sources exhibit anti-androgen activity by inhibiting steroid 5-alpha reductase, identifying key structural features for their potency and safety in treating androgen-related conditions.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.